About Genuity Science
Genuity Science is a Healthcare company based in Boston (United States) founded in 2013 by Jeff Gulcher, and was acquired by Hibercell in August 2021. AI-based omics data analysis solutions are provided to researchers. Genuity Science has raised $515 million across 3 funding rounds from investors including Temasek, HiberCell and Ireland Strategic Investment Fund. Genuity Science has completed 1 acquisition, including Genomics Medicine Ireland. Its chief executive, as recorded, is Rob Brainin. Genuity Science offers products and services including Target Discovery, Portfolio Optimization, Clinical Trials, and Biomarker Discovery. Its focus areas include HealthTech, Life Sciences Tech, Research & Development and Drug Informatics. Its competitors include Helix, Benchling and BioAge Labs; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2013 and based in Boston, United States, Genuity Science operates in the biotechnology sector. Omics data, including genomic and phenotypic information, is analyzed through AI-driven tools. These solutions support drug discovery, design, and development, as well as clinical trial studies and broader genomic research. Services are tailored for researchers seeking efficient data interpretation in scientific applications.
- Headquarters Boston, United States
- Founders Jeff Gulcher
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website genuitysci.com
- Social LinkedIn Facebook
- Acquired by Hibercell (Aug 2021)
Products & Services of Genuity Science
Genuity Science offers a comprehensive portfolio of products and services, including Target Discovery, Portfolio Optimization, Clinical Trials, and Biomarker Discovery.
Identifies novel targets using genetic evidence for drug development research.
Validates targets and biomarkers to optimize research investments effectively.
Designs studies by identifying sub-populations for better trial outcomes.
Discovers biomarkers for disease stratification and targeted therapies.
Funding Insights of Genuity Science
Genuity Science has successfully raised a total of $515M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $200 million completed in November 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $515M
- Total Rounds 3
- Last Round Series C — $200M
- First Round $75M
(May 2017)
- Investors Count 6
All 3 funding rounds of Genuity Science with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2018 | $200M | Series C | – | Ireland Strategic Investment Fund | |
| Sep 2017 | $240M | Series B | – | Sequoia Capital | |
| May 2017 | $75M | Series B | – | Temasek, Yunfeng Capital |
7 investors in total: 7 institutional.
Investors in Genuity Science
Genuity Science has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Temasek, HiberCell and Ireland Strategic Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
An investment platform is provided for diverse sectors and geographies. | 1974 | temasek.com.sg | Singapore, Singapore | |
Private equity investments are managed by Yunfeng Capital in China. | yfc.cn | Shanghai, China | ||
Sequoia Capital is engaged in venture capital investments. | 1972 | sequoiacap.com | ||
| 3wpcap.com | ||||
Venture capital investments are facilitated by Amgen-backed entity. | amgenbd.com | Thousand Oaks, United States | ||
Operates as Ireland's strategic investment fund, managing key financial investments for national development. | 1990 | isif.ie | Dublin, Ireland | |
HiberCell is focused on developing cancer treatment therapies. | 2015 | hibercell.com | New York, United States |
Investor details for Genuity Science
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genuity Science
32 people are tracked at Genuity Science (13 in leadership, 11 in board & advisors, 8 in team).
| Name | Role | Group |
|---|---|---|
Jeff Gulcher | Co-Founder & CSO | Leadership |
Rob Brainin | CEO | Leadership |
Beth Johnson | Executive Assistant & Head Of Administrative Operations | Leadership |
Michael Danielson | Executive Director Head Of CMC | Leadership |
Jeremy Drees | Director, Translational Medicine | Leadership |
Ari Nowacek | Co-Founder & Chief Business Officer | Leadership |
Crissy Dudgeon | Associate Director, InVitro Translational Oncology | Leadership |
Alexander Conte | Associate Director, Business Development | Leadership |
Nandita Bose | VP of Translational Immunology | Leadership |
José Iglesias | Consultant Chief Medical Officer | Leadership |
Eric Lightcap | Vice President | Leadership |
Haiguo Wu | Director of Bioinformatics | Leadership |
Kyle Michel | Associate Director, CMC Operations | Leadership |
Julio Aguirre-Ghiso | Co-Founder & Scientific Advisor | Board & advisors |
Christoph Klein | Scientific Advisor | Board & advisors |
Cindy Jacobs | Director | Board & advisors |
Jim Sullivan | Director | Board & advisors |
Colin Goddard | Director | Board & advisors |
Lisa M. Coussens | Scientific Advisor | Board & advisors |
Philip Rowlands | Scientific Advisor | Board & advisors |
12 more people are available in the full profile.
Complete people profiles for Genuity Science
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genuity Science
Genuity Science has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Genomics Medicine Ireland.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Population genomics database for disease risk analysis is developed. | genomicsmed.ie | Dublin, Ireland | 2015 | Nov 2018 | •••• |
Complete acquisition details for Genuity Science
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genuity Science
5 dated milestones of Genuity Science across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Genuity Science is founded.
- Funding First funding round of $75.0M.
- Funding Latest funding round, Series C, of $200.0M.
- Acquisition Acquires Genomics Medicine Ireland.
- Exit Acquired by Hibercell.
Competitors of Genuity Science
Genuity Science has 3 listed competitors in our database, 3 of them funded. They include Helix, Benchling and BioAge Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| helix.com | 2015 | San Francisco, United States | $435M | Genomic database for clinical research is provided. | ||
| benchling.com | 2012 | San Francisco, United States | $411.9M | 640 | Cloud-based bioinformatics platform is offered for biotech research. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. |
Detailed competitors of Genuity Science
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Genuity Science
The website of Genuity Science (genuitysci.com) receives about 2K visits a month and ranks #13,240,613 among all websites worldwide, #8,396 in Biotechnology and Pharmaceuticals.
- Monthly visits2K
▲ 90% vs previous month
- Global rank#13,240,613
among all websites
- Category rank#8,396
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.5
- Average visit44 sec
- DevicesDesktop 36% · Mobile 64%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Genuity Science (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genuity Science
Complete news archive for Genuity Science
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genuity Science
Genuity Science was founded in 2013 and raised its 1st funding round 4 years after it was founded.
Genuity Science is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Rob Brainin is the CEO of Genuity Science, as recorded in our data.
Genuity Science is a funded company, having raised a total of $515M across 3 funding rounds to date. The company's 1st funding round was a Series B of $75M, raised on May 2017.
Founded in 2013 and based in Boston, United States, Genuity Science operates in the biotechnology sector. Omics data, including genomic and phenotypic information, is analyzed through AI-driven tools. These solutions support drug discovery, design, and development, as well as clinical trial studies and broader genomic research. Services are tailored for researchers seeking efficient data interpretation in scientific applications.
Genuity Science's top competitors include Helix, Benchling and BioAge Labs.
Genuity Science offers Target Discovery, Portfolio Optimization, Clinical Trials, and Biomarker Discovery.
Genuity Science has made 1 acquisition, including Genomics Medicine Ireland.
Genuity Science has 7 investors. Key investors include Temasek, HiberCell, Ireland Strategic Investment Fund, Yunfeng Capital, and Sequoia Capital.
Yes. Genuity Science was acquired by Hibercell in August 2021.